Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA gives go-ahead for Levacor trial

This article was originally published in Clinica

Executive Summary

WorldHeart is to begin a US bridge-to-transplant study of its levitating ventricular assist device (VAD), Levacor, after receiving conditional study approval from the FDA. Salt Lake City, Utah-based WorldHeart must first pass some additional data to the FDA – it has 45 days in which to do so – but the study may begin upon the agency's receipt of clinical centre institutional review board approvals. The trial will enrol 200 subjects, and an interim analysis of the first 150 subjects is planned. The study has been assigned CMS category B2, which makes insurance reimbursement possible.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel